Fresenius Medical Care Appoints Rex Liu as New VP of Commercial Operations for China & Hong Kong Following Alan Chen's Retirement

Source:Instrument Family,Reproduction without authorization is prohibited, and reproduction is allowed 24 hours later.

Global dialysis giant Fresenius Medical (Fresenius Medical Care) Recently announced important personnel changes:Head of Commercial Operations, China and Hong KongAlan Chen(Chen Yugang) in service companies12Retirement is imminent after the Spring Festival,Rex Liu(Liu Weiting) has been5Month11Officially assumed the position on [date], serving as Vice President of Commercial Operations for China and Hong Kong (VP Commercial Operations, China & Hong Kong）。

According to official disclosure from Fresenius Medical Care, Yungang Chen is employed by the company.12During the year, especially during multiple organizational changes and strategic adjustments, he/she played a prominent leadership role, ensuring the implementation of local business in China while maintaining high synergy with the group's global strategic priorities. The company praised him/her for being adept at building solid trust relationships among various teams and partners, which played a crucial role in strengthening collaboration within regional and global organizations.

Fresenius Medical Care expressed gratitude for Chen Yugang's contributions and wished him a smooth retirement.

Successor Liu Weiting has深耕ed the medical industry for over16Years, with rich experience in senior management.

Public information shows that, before joining Fresenius Medical Care, Wei-Cheng Liu served at Abbott (Abbott) General Manager of Rhythm Management Business in Greater China, responsible for leading a large cross-functional team, with extensive experience in commercial implementation and refined operational management, and skilled at navigating the complex healthcare market environment driven by policy.

Before joining Abbott, Liu Weiting had previously worked at B. Braun Medical (B.Braun Medical), Boston Scientific (Boston Scientific), Medtronic (Medtronic) and other global leading medical device companies, holding management positions in multiple business lines such as sales and marketing, successfully contributing to the launch of multiple products and drivingInnovative HealthcareDevelopment and Commercialization of Solutions.

As the second-largest medical device market globally, the Chinese market has always been the strategic focus for multinational healthcare companies. Fresenius Medical Care, the world's largest provider of dialysis services, is transitioning its head of commercial operations in China, amid a period of profound adjustment in the Chinese healthcare industry.——The normalization of centralized procurement, the continuous advancement of medical insurance payment reform, and the acceleration of domestic substitution, among other overlapping factors, have placed higher demands on the localized operational capabilities of foreign enterprises in China.

Liu Weiting's previous cross-functional management experience in multiple multinational medical device companies, as well as his deep understanding of China's policy environment, is expected to provide strong support for the next phase of Fresenius Medical Care’s business development in China.